India Monoclonal Antibodies Market to Grow with a CAGR of 5.72% through 2030
Increasing Healthcare Awareness is expected to drive the India
Monoclonal Antibodies Market growth in the forecast period, 2026-2030.
According to TechSci Research report, “India
Monoclonal Antibodies Market- By Region, Competition, Forecast and
Opportunities, 2020-2030”, the India Monoclonal Antibodies Market
was valued
at USD 208.58 Million in 2024 and is anticipated to grow with a CAGR of 5.72 % through
2030. Rising
healthcare awareness is a key driver for the monoclonal antibodies (mAb) market
in India. As the population becomes more informed about advanced medical
treatments, there is a growing demand for effective therapies, particularly for
complex diseases such as cancer, autoimmune disorders, and chronic conditions.
Patients are increasingly seeking targeted treatments that deliver improved
outcomes with fewer side effects compared to traditional options.
Public and private healthcare
institutions, as well as non-governmental organizations, are actively promoting
the benefits and availability of advanced therapies like monoclonal antibodies.
The widespread use of digital platforms, healthcare apps, and social media has
made information about mAb treatments more accessible, empowering patients to
pursue specialized care. As new treatments gain visibility, both patients and
healthcare professionals are becoming more aware of medical innovations, which
drives the demand for advanced therapies like mAbs. Improved healthcare
infrastructure and the growing availability of hospitals offering cutting-edge
treatments are encouraging patients to explore these newer therapies. As
awareness continues to rise, patients are becoming better informed about
available treatment options, including monoclonal antibodies, which are
increasingly recognized for their precision and effectiveness in treating
severe and chronic diseases. This trend is fueling the continued growth of the
mAb market in India.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "India Monoclonal Antibodies Market”
The India Monoclonal Antibodies Market is segmented
into type, application, production, biomanufacturing, end user, regional distribution,
and company.
Based on the production, in
vitro emerged as the dominating segment in the India Monoclonal Antibodies market
in 2024. In vitro production methods, utilizing cell-based systems like mammalian
or bacterial cultures, are more cost-effective and scalable compared to in vivo
methods, making them ideal for both research and large-scale manufacturing.
With improvements in cell culture techniques and bioreactor technologies, in
vitro production has become increasingly efficient, enabling the faster
production of high-quality monoclonal antibodies. This method has been
well-established for many years, with reliable and proven processes, making it
the preferred choice for most pharmaceutical and biotech companies,
particularly for therapeutic mAbs and biosimilars. In vitro methods also
typically comply more easily with regulatory standards, avoiding the ethical
and safety complexities associated with in vivo methods. As a result, in vitro
production is the dominant method for large-scale commercial manufacturing,
even though in vivo production is still used in certain preclinical stages.
Based on the region, the West emerged as the fastest
growing region in the India Monoclonal Antibodies market during the forecast
period. The West region, particularly cities like Mumbai, Pune, and Ahmedabad,
is recognized for its rapidly advancing healthcare infrastructure. These cities
host some of India’s leading hospitals, research centers, and biotech parks,
which are driving the rising demand for monoclonal antibody therapies. The
region also has a high concentration of top pharmaceutical companies, many of
which are focused on the development and production of monoclonal antibodies.
States like Maharashtra, Gujarat, and others in the West have become prominent
pharmaceutical hubs, catering to both domestic and international markets.
Additionally, significant investments in research and development, particularly
in monoclonal antibody production and biosimilars, are boosting the region’s
capabilities. The presence of major biotech and pharmaceutical players has
strengthened the West’s ability to develop, manufacture, and commercialize mAb
products. Increasing awareness of advanced therapies, along with improved
healthcare access, is further driving the adoption of monoclonal antibodies. These
factors make the West the fastest-growing region for monoclonal antibodies in
India, supported by a strong healthcare and pharmaceutical ecosystem and
increasing demand for targeted treatments.
Major companies operating in India Monoclonal
Antibodies Market are:
- Dr.
Reddy's Laboratories Ltd.
- Bristol
Myers Squibb India Pvt. Ltd.
- Roche
India Pvt. Ltd.
- Intas
Pharmaceuticals Limited
- Merck
India
- Eli
Lilly, and Company (India) Private Limited
- Biocon
Limited
- AstraZeneca
India Pvt. Ltd.
- Pfizer
Limited
Download Free Sample Report
Customers can also request 10% free
customization on this report
“The monoclonal antibodies (mAb) market in India is
experiencing rapid evolution, driven by the increasing demand for precision
medicine and the country’s growing healthcare infrastructure. With rising
incidences of chronic diseases like cancer and autoimmune disorders, the need
for targeted therapies has surged. India’s strong biotechnology sector,
supported by government initiatives and a skilled workforce, has made it a hub
for mAb development, particularly in the biosimilar space. As healthcare access
improves and awareness increases, patients are seeking advanced treatment
options, creating significant opportunities for mAb manufacturers. The ongoing
expansion of clinical trials and R&D investments further strengthens
India’s position in this market,” said Mr. Karan Chechi, Research Director of
TechSci Research, a research-based management consulting firm.
“India Monoclonal Antibodies Market By Type (Murine,
Chimeric, Humanized, Human), By Application (Cancer, Cardiac/Cardiovascular,
Neurological, Others), By Production (In vitro, In vivo), By Biomanufacturing
(Originator, CMO), By End User (Hospitals, Research Laboratories, Others), By
Region, Competition, Forecast and Opportunities, 2020-2030”, has evaluated
the future growth potential of India Monoclonal Antibodies Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in India Monoclonal Antibodies Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com